Zoetis PT Lowered to $37.00 (ZTS)
Equities research analysts at Jefferies Group reduced their price target on shares of Zoetis (NYSE:ZTS) from $38.00 to $37.00 in a research note issued to investors on Monday. Jefferies Group’s target price points to a potential upside of 14.48% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Zoetis in a research note on Wednesday, August 6th. They now have a $34.00 price target on the stock. Analysts at BMO Capital Markets cut their price target on shares of Zoetis from $37.00 to $36.00 in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $29.80.
Zoetis (NYSE:ZTS) traded up 0.53% on Monday, hitting $32.49. 660,637 shares of the company’s stock traded hands. Zoetis has a 52-week low of $28.14 and a 52-week high of $33.35. The stock’s 50-day moving average is $32.59 and its 200-day moving average is $30.89. The company has a market cap of $16.278 billion and a P/E ratio of 30.78.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, September 2nd. Stockholders of record on Wednesday, August 20th will be paid a dividend of $0.072 per share. This represents a $0.29 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, August 18th.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.